

FIJISHI

---

# Accelerating Rare Disease Drug Repurposing.

*India, 14 March 2025/ 01:22 PM IST*

*Disclaimer: The following is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, and timing of any features or functionality described for Fijishi's products remains at the sole discretion of Fijishi.*

## Case Study: Accelerating Rare Disease Drug Repurposing

**Type of Organization:** Biotech Startup

**Industry:** Pharmaceutical / Rare Diseases

**The Challenge:** Identifying existing, approved drugs that could be repurposed for a very rare, previously untreatable orphan disease. Traditional methods involved labor-intensive manual literature reviews and speculative *in vitro* screening, which were slow and often unproductive due to limited mechanistic understanding of the disease.

**The ScieFI Solution:** The startup deployed **ScieFI's Adaptive Knowledge Graph (AKG)** and **AI Co-Scientist Module (ACS)**. The AKG ingested all available public omics data, patient registry data, and drug databases, including off-target interaction profiles. Its **cross-disciplinary semantic bridging** identified subtle molecular commonalities between the rare disease's pathology and known mechanisms of action for existing drugs in unrelated therapeutic areas. The ACS's **Intelligent Hypothesis Generation** then proposed a prioritized list of repurposing candidates with high confidence scores, complete with predicted molecular interactions. It further designed a streamlined set of *in vitro* validation experiments, outlining optimal cell lines and readouts.

**Impact & Benefits:** This approach drastically reduced the initial drug screening phase from over a year to just three months. The startup identified two highly promising drug candidates for rapid preclinical validation, one of which had already completed Phase II trials for a different indication, significantly de-risking and accelerating the path to patient impact for a previously neglected disease.

### Key Features Highlighted:

- Adaptive Knowledge Graph (AKG)
- Cross-disciplinary semantic bridging
- AI Co-Scientist Module (ACS)
- Intelligent Hypothesis Generation
- Automated Experimental Design & Optimization

---

*This document is provided for information purposes only. This document is not warranted to be error-free, nor subject to any other warranties or conditions, whether expressed orally or implied in law, including implied warranties and conditions of merchantability or fitness for a particular purpose. We specifically disclaim any liability with respect to this document and no contractual obligations are formed either directly or indirectly by this document. This document may not be reproduced or transmitted in any form or by any means, electronic or mechanical, for any purpose, without our prior written permission. To know more, please visit [www.fijishi.com](http://www.fijishi.com)*

**©2025 Fijishi, and/or its affiliates. All rights reserved.**